Kallyope
Overview
Kallyope develops neuromodulation therapies and bioelectronic medicine platforms that leverage neural signaling to treat gastrointestinal and metabolic disorders. The company combines neuroscience research with implantable and wearable device technology to create targeted interventions for chronic disease management.
More in Neurotechnology
Latest industry news
BlueWind Medical's Revi Extend Wins FDA Clearance, Extending Implant Life to 15 Years
2026-08-06 · Product
Neurofeedback Systems Market Eyes $2.95 Billion Valuation by 2035 as Clinical and Consumer Demand Converge
2026-08-05 · Industry
Smaller Neuromodulation Devices Are Reshaping the Competitive Landscape for TMS Providers
2026-08-04 · Industry
NIH-Backed Brain-Computer Device Restores Speech in Paralyzed Patient
2026-08-03 · Research
Company details
Category
🏢 Neurotechnology
Funding
Private
Listed
2026-07-29
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →